ELDN Eledon Pharmaceuticals, Inc. Common Stock

XNAS 2.21 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ELDN $2.21 —
Key stats
$2.21
Pre-market $2.28 +3.17%
52-Week Range
$1.35 – $4.60
YTD
+36.11%
IV Rank (30D)
47.06
Straddle Price
$0.93
P/C Vol Ratio
3.60
Market Cap
$0.2B
Open
$2.33
Day Range
$2.20 – $2.37
Volume
654,702
Prev Close
$2.30
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.94
Cost of Equity (CAPM)9.66% (VRP-adj)
WACC9.81%
Volatility Risk Premium+153.4pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-292.1%
Book / Price23.2%
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$2.75 (Market Anchor value)
SMA 20 / Bollinger Mid$2.36
Bollinger Width / SMA20868.2% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Blended Fair Value
—
Deviation
—
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $2.75 0% stability 0% (BB-width)
Options Expected (B-L 30d) $2.17 0% 5 strikes · skew +0.23
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.2B
Employees
33
List Date
2014-09-17
CIK
0001404281
Next Earnings
2026-11-13 (After-Close)
EPS Forecast
($0.20) (1 est.)
Headquarters
Irvine, CA
Homepage
https://www.eledon.com

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to trea…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-1.79%-14.92%46.26%-5.32%5.36%35.80%10.90%
Feb4.28%-11.08%-23.38%1.69%-6.95%14.91%-3.42%
Mar-30.29%11.93%2.61%27.95%-15.36%15.79%2.10%
Apr-14.89%-22.73%-3.23%20.10%-1.86%21.33%-0.21%
May-3.94%7.41%-8.70%20.09%-8.54%3.25%1.60%
Jun-14.76%-24.34%-30.46%-5.71%-11.44%4.79%-13.65%
Jul-15.49%22.86%-1.43%17.13%12.90%-13.89%3.68%
Aug24.74%23.76%16.92%-2.77%-23.37%-13.12%4.36%
Sep-24.91%-23.12%-2.84%-9.12%1.57%-15.95%-12.40%
Oct-16.67%-12.36%0.65%90.57%62.41%-9.24%*19.23%
Nov-3.55%-0.41%-14.81%-12.08%-62.61%---18.69%
Dec-6.77%-7.51%57.89%-5.72%-1.31%--7.32%
Total-70.49%-49.82%7.10%173.90%-65.26%35.37%5.13%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.36
SMA 50: $2.75
SMA 200: $3.09
Current: $2.21
EMA 12: $2.30
EMA 26: $2.44
MACD: -0.1471 | Signal: 0.0173
BEARISH
ADX (14): 19.98
RANGE
+DI: 12.78
−DI: 18.25

Momentum Oscillators

RSI (14): 33.49
NEUTRAL
Stoch %K: 34.04
Stoch %D: 35.34
Williams %R: -78.72

Volume & Volatility

BB Upper: $2.60
BB Lower: $2.12
NEUTRAL
OBV: 15,591,120
Vol SMA 20: 740,398
Vol ROC: 48.30%
ATR: $0.15
True Range: $0.17
HV 20: 46.5%
HV 30: 48.4%
HV 60: 44.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall assessment: BEARISH (6/10)

Key drivers and primary risks:

  • Weak technical signals, including a bearish MACD and RSI below 50
  • High volatility and beta indicate potential for large price swings
  • Recent news headlines are generally positive, but the stock's price action suggests caution

Investment thesis: The stock is at risk of further decline due to weak technical indicators and high volatility.

Recent news sentiment impact: Positive news headlines may not be enough to overcome the bearish technical signals and high volatility.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): BEARISH, Medium-term (1-3 months): NEUTRAL, Long-term (3-12 months): BULLISH

Support/Resistance Levels: Key price levels include:

  • SMA 20: $3.39
  • SMA 50: $3.61
  • Upper Bollinger Band: $3.94

Momentum Signals:

  • RSI interpretation: Oversold (<30)
  • MACD signal: Bearish (below signal line)
  • Bollinger Bands position: Squeeze

Volume Analysis: Volume trends and institutional interest signals are mixed, but the stock is not showing strong buying pressure.

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines from Eledon Pharmaceuticals' recent business highlights and Phase 2 trial results for Tegoprubart.

Sentiment Assessment: Aggregate news sentiment is POSITIVE (70%).

Catalyst Identification: Upcoming events include the Cantor Global Healthcare Conference 2025, which may provide further insight into the company's growth prospects.

Market Narrative: The positive news headlines are not currently driving significant price movements, as the stock's technical signals remain bearish.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta >1.8).

Volatility Regime: Current volatility is high compared to historical levels.

Options Market Signals:

  • IV rank: 16.8% (Low)
  • Put/call ratios: Bullish sentiment
  • Unusual activity: None

Downside Protection: Support levels include SMA 20 and the lower Bollinger Band at $2.85.

Market Context & Positioning

Sector Performance: The healthcare sector is performing well, but Eledon's stock price has not kept pace with its peers.

Institutional Activity: Institutional investors are showing limited interest in the stock, as seen by the low volume flow and open interest levels.

Correlation Analysis: Correlation with SPY (S&P 500) is relatively low at 0.28, indicating potential for independent price movements.

Relative Valuation: The stock appears to be trading within a range, but lacks clear support or resistance levels.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $3.39
  • SMA 50: $3.61
  • Upper Bollinger Band: $3.94

Breakout/Breakdown Levels: Technical breakdown below the lower Bollinger Band at $2.85 or a breakout above the upper band.

Time-Sensitive Catalysts: Upcoming events, such as the Cantor Global Healthcare Conference 2025, may provide further insight into the company's growth prospects.

Risk Management: Stop-loss levels should be set around $2.85 to protect against potential losses. Position sizing considerations include limiting exposure and focusing on risk-reward analysis.

By combining technical, fundamental, and sentiment analysis, this report provides a comprehensive view of Eledon Pharmaceuticals' stock performance. The bearish technical signals, high volatility, and mixed institutional activity suggest caution, while the positive news headlines may not be enough to overcome these risks.

Generated
News
All ELDN news →
Showing 1–10 of 50
Page 1 of 5
Earnings History
11 of 12 under expected move
Avg Expected Move
39.48%
Avg Actual Move
6.53%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-08-12 After-Close 25.71% 0.79% 0.03x Within
2022-03-24 After-Close 40.80% 4.00% 0.10x Within
2023-11-09 After-Close 117.39% 0.87% 0.01x Within
2024-08-14 After-Close 24.07% 1.48% 0.06x Within
2024-11-12 After-Close 6.22% 11.41% 1.83x Exceeded
2025-03-20 After-Close 21.08% 2.03% 0.10x Within
2025-05-14 After-Close 96.29% 2.12% 0.02x Within
2025-08-14 After-Close 6.73% 1.15% 0.17x Within
2025-11-07 Pre-Market 56.71% 49.76% 0.88x Within
2026-03-19 After-Close 14.04% 1.05% 0.07x Within
2026-05-13 After-Close 30.28% 1.80% 0.06x Within
2026-08-13 Pre-Market 34.48% 1.86% 0.05x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ELDN Options Activity & IV Rank

ELDN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 145.5%
7-DTE IV: —
Expected Move: $0.93
7-DTE Move: $0.93
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 15
Put Volume: 54
P/C Volume: 3.6
BEARISH
Call OI: 7,976
Put OI: 373
P/C OI: 0.047
Total OI: 8,349

ATM Options Pricing

ATM Call: $0.42
ATM Put: $0.50
Call %: 19.3%
Put %: 22.7%

Chain Summary

Chain Volume: 348
Chain OI: 11,015
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 65th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
65%
vs own history
GEX tilt
+0.77
OI-weighted, today
Vanna tilt
+0.74
δ-sensitivity to IV
Charm tilt
-0.78
δ-decay vs time
Vanna tilt +0.74: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.78: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 4k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 140.3% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)47.1MediumOct 26
Straddle Price (30 DTE)$0.93Oct 26
Beta Analysis

Risk Metrics

Beta: 1.7287
Alpha: -27.89%
Correlation: 0.2673
R-Squared: 7.1%
Stock Volatility: 82.4%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ELDN
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$3.9M
0.00%
#2214 of 3716new13F
Citadel Hedge fund
Ken Griffin
$851K
0.00%
#3886 of 6285new13F
Renaissance Technologies Hedge fund
Jim Simons
$792K
0.00%
#2420 of 3138+716.7%13F
Rockefeller Capital Management Family office
Rockefeller family
$286K
0.00%
#2406 of 4729+1.4%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ELDN Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 87,143,148 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

163 filers51,023,733 shares$190.14M value58.55% of float
# Filer Shares Value % of Total % of Float Period
1 BVF INC/IL 6,293,282 $24.80M 13.04% 7.22% 2026-06-30
2 BlackRock, Inc. Custodian 5,123,842 $20.19M 10.62% 5.88% 2026-06-30
3 Defilade Capital Management, L.P. 3,525,338 $13.89M 7.31% 4.05% 2026-06-30
4 Vanguard Capital Management LLC 3,417,223 $13.46M 7.08% 3.92% 2026-06-30
5 Goldman Sachs Group Inc Custodian 2,510,308 $9.89M 5.20% 2.88% 2026-06-30
6 Ensign Peak Advisors, Inc 2,101,224 $8.28M 4.35% 2.41% 2026-06-30
7 Geode Capital Management, LLC Custodian 1,956,601 $7.71M 4.06% 2.25% 2026-06-30
8 Catalio Capital Management, LP 1,695,071 $6.68M 3.51% 1.95% 2026-06-30
9 State Street Corp 1,621,969 $6.39M 3.36% 1.86% 2026-06-30
10 Zimmer Partners, LP 1,596,599 $6.29M 3.31% 1.83% 2026-06-30
11 Vanguard Group Inc Custodian 4,039,686 $6.10M 3.21% 4.64% 2025-12-31
12 SPHERA FUNDS MANAGEMENT LTD. 1,191,187 $4.69M 2.47% 1.37% 2026-06-30
13 AWM Investment Company, Inc. 1,100,000 $4.33M 2.28% 1.26% 2026-06-30
14 UBS Group AG Custodian 1,048,245 $4.13M 2.17% 1.20% 2026-06-30
15 KINGDON CAPITAL MANAGEMENT, L.L.C. 1,039,275 $4.09M 2.15% 1.19% 2026-06-30
16 Millennium Management LLC Custodian 979,712 $3.86M 2.03% 1.12% 2026-06-30
17 Bank of America Corp Custodian 883,097 $3.48M 1.83% 1.01% 2026-06-30
18 ADAR1 Capital Management, LLC 647,812 $2.55M 1.34% 0.74% 2026-06-30
19 22NW, LP 636,364 $2.51M 1.32% 0.73% 2026-06-30
20 Northern Trust Corp Custodian 616,399 $2.43M 1.28% 0.71% 2026-06-30
21 AQR Capital Management, LLC Custodian 581,028 $2.29M 1.20% 0.67% 2026-06-30
22 CM Management, LLC 575,000 $2.27M 1.19% 0.66% 2026-06-30
23 Blue Owl Capital Holdings LP 566,509 $2.23M 1.17% 0.65% 2026-06-30
24 Dimensional Fund Advisors LP Custodian 538,738 $2.12M 1.12% 0.62% 2026-06-30
25 Vanguard Portfolio Management LLC 533,365 $2.10M 1.11% 0.61% 2026-06-30
7 filers$942.36K notional
# Filer Notional Value % of Total Period
1 Blue Owl Capital Holdings LP $285.00K 30.24% 2026-06-30
2 GROUP ONE TRADING LLC Custodian $270.68K 28.72% 2026-06-30
3 Susquehanna International Group, LLP Custodian $236.01K 25.04% 2026-06-30
4 Citadel Advisors LLC Custodian $60.28K 6.40% 2026-06-30
5 Jane Street Group, LLC Custodian $57.52K 6.10% 2026-06-30
6 Simplex Trading, LLC Custodian $30.34K 3.22% 2026-06-30
7 Triumph Capital Management $2.53K 0.27% 2026-09-30
6 filers$5.46M notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $1.26M 23.01% 2026-06-30
2 Citadel Advisors LLC Custodian $1.10M 20.17% 2026-06-30
3 Jane Street Group, LLC Custodian $1.10M 20.07% 2026-06-30
4 Susquehanna International Group, LLP Custodian $978.30K 17.93% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $847.49K 15.53% 2026-06-30
6 Wolverine Trading, LLC Custodian $179.32K 3.29% 2025-09-30

ELDN Insider Trading (Form 4)

Latest: 2026-08-04
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-04 Steven Perrin President Mixed +80,215 $3.38 -$243.8K EDGAR
2026-08-04 David-Alexandre C Gros Chief Executive Officer Mixed +159,663 $3.38 -$658.4K EDGAR
2026-01-16 John S. McBride Director Exer (M) +3,430 — EDGAR
2026-01-16 June Lee Director Exer (M) +3,430 — EDGAR
2026-01-16 Jan Hillson Director Exer (M) +3,430 — EDGAR
2026-01-16 Keith Katkin Director Exer (M) +8,575 — EDGAR
2026-01-16 James A. Robinson Jr. Director Exer (M) +3,430 — EDGAR
2026-01-16 Allan Kirk Director Exer (M) +3,430 — EDGAR
2025-01-13 June Lee Director Grant (A) +34,300 RSU — EDGAR
2025-01-13 Paul Sean Little Chief Financial Officer Grant (A) +250,000 RSU — EDGAR
2025-01-13 Bryan E. Smith General Counsel, Corporate Sec Grant (A) +215,000 opt — EDGAR
2025-01-13 John S. McBride Director Grant (A) +34,300 opt — EDGAR
2025-01-13 James A. Robinson Jr. Director Grant (A) +34,300 opt — EDGAR
2025-01-13 Jan Hillson Director Grant (A) +34,300 RSU — EDGAR
2025-01-13 Allan Kirk Director Grant (A) +34,300 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ELDN Insider Holdings

10 insiders · @ $2.21
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 BVF INC/IL 10%+ Owner 2,633,679 $5.82M $0 1 2024-10-31
2 David-Alexandre C Gros Chief Executive Officer 363,454 $803.2K $57.8K 10 2026-08-04
3 Steven Perrin President 81,215 $179.5K $2.6K 8 2026-08-04
4 Paul Sean Little Chief Financial Officer 10,000 $22.1K $88.7K 7 2025-01-13
5 Keith Katkin Director 8,575 $19.0K $0 5 2026-01-16
6 John S. McBride Director 3,430 $7.6K $0 5 2026-01-16
7 June Lee Director 3,430 $7.6K $0 5 2026-01-16
8 James A. Robinson Jr. Director 3,430 $7.6K $0 3 2026-01-16
9 Jan Hillson Director 3,430 $7.6K $0 5 2026-01-16
10 Allan Kirk Director 3,430 $7.6K $0 3 2026-01-16
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ELDN Board & Officers

As of SEC filings through Aug 4, 2026

Directors 8

Officers 2

Changes in the last 10 years (50)
Oct 2, 2023Allan Kirk became a director
Oct 1, 2023James A. Robinson Jr. became a director
Apr 26, 2023The company announced the departure of Gary A Lyons from the board in an SEC filing
Feb 2, 2022Bryan E. Smith listed as General Counsel, Corporate Sec (previously General Counsel, Corporate Secretary, and Chief Compliance Officer) in SEC filings
Jan 31, 2022Mark N Lampert first listed as a 10% owner in an SEC filing
Jan 31, 2022Bvf Partners L P/il first listed as a 10% owner in an SEC filing
Jan 31, 2022Bvf Inc/il first listed as a 10% owner in an SEC filing
Jan 31, 2022Bvf Gp Holdings LLC first listed as a 10% owner in an SEC filing
Jul 1, 2021Jan Hillson became a director
Apr 19, 2021Bryan E. Smith became General Counsel, Corporate Secretary, and Chief Compliance Officer
Mar 15, 2021Paul Sean Little became Chief Financial Officer
Dec 28, 2020Mark N Lampert reported in an SEC filing no longer being a 10% owner
Dec 28, 2020Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner
Dec 28, 2020Bvf Inc/il reported in an SEC filing no longer being a 10% owner
Dec 28, 2020Bvf Gp Holdings LLC reported in an SEC filing no longer being a 10% owner
Dec 8, 2020June Lee became a director
Dec 4, 2020OrbiMed Israel GP Ltd. reported in an SEC filing no longer being a director
Dec 4, 2020OrbiMed Israel GP Ltd. reported in an SEC filing no longer being a 10% owner
Dec 4, 2020OrbiMed Israel BioFund GP Limited Partnership reported in an SEC filing no longer being a director
Dec 4, 2020OrbiMed Israel BioFund GP Limited Partnership reported in an SEC filing no longer being a 10% owner
Not reported recently (15)
  • Paul Sean Little · Last reported as Chief Financial Officer in an SEC filing dated Jan 13, 2025
  • Bryan E. Smith · Last reported as General Counsel, Corporate Sec in an SEC filing dated Jan 13, 2025
  • Bvf Gp Holdings LLC · Last reported as a 10% owner in an SEC filing dated Oct 31, 2024
  • Bvf Partners L P/il · Last reported as a 10% owner in an SEC filing dated Oct 31, 2024
  • Mark N Lampert · Last reported as a 10% owner in an SEC filing dated Oct 31, 2024
  • Bvf Inc/il · Last reported as a 10% owner in an SEC filing dated Oct 31, 2024
  • Walter C Ogier · Last reported as a director in an SEC filing dated May 2, 2023
  • Logos Global Management LP · Last reported as a 10% owner in an SEC filing dated Nov 6, 2020
  • Jon Kuwahara · Last reported as Senior Vice President of Finance and Administration in an SEC filing dated Sep 15, 2020
  • Gregory J. Flesher · Last reported as a director in an SEC filing dated Mar 20, 2020
  • Catherine C. Turkel · Last reported as President in an SEC filing dated Mar 20, 2020
  • Erez Chimovits · Last reported as a director in an SEC filing dated Feb 25, 2020
  • Cheryl Cohen · Last reported as a director in an SEC filing dated Jul 15, 2019
  • Jodie Pope Morrison · Last reported as a director in an SEC filing dated Jul 5, 2017
  • Christine Ocampo · Last reported as Chief Financial and Compliance Officer in an SEC filing dated May 26, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
22 ETFs hold ELDN
22 shown · $17.91M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $6.3M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $4.6M $74.6B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $2.2M — 2026-09-30
4 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.01% $1.7M $13.7B 2026-10-23
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.1M — 2026-09-30
6 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $578,986 — 2026-10-23
7 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.04% $535,978 $1.2B 2026-10-23
8 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.02% $257,391 $1.0B 2026-10-23
9 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.01% $216,765 — 2026-09-30
10 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.00% $210,655 $6.6B 2026-10-23
11 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $105,108 — 2026-10-23
12 RSSL Global X Russell 2000 ETF Global X 0.01% $83,198 — 2026-10-26
13 OMFS Invesco Russell 2000 Dynamic Multifactor ETF Invesco 0.02% $40,862 — 2026-10-24
14 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $18,730 — 2026-09-30
15 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $9,830 — 2026-10-23
16 ITWO ProShares Russell 2000 High Income ETF ProShares 0.01% $9,733 — 2026-10-26
17 URTY ProShares UltraPro Russell2000 ProShares 0.00% $7,468 — 2026-10-26
18 UWM ProShares Ultra Russell2000 ProShares 0.00% $5,249 — 2026-10-26
19 AVUC Avantis U.S. Core Equity ETF Avantis 0.00% $2,758 $361.4M 2026-10-23
20 RESM Columbia Research Enhanced Small Cap ETF Nport 0.01% $339 — 2026-06-30
21 HDG ProShares Hedge Replication ETF ProShares 0.00% $206 — 2026-10-26
22 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.01% $66 — 2026-10-26
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.77
TTM Revenue
—
TTM Net Income
$-76.55M
TTM Op. Cash Flow
$-68.89M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-36.94M$-0.33$-22.61M
Q4 '252025-12-31—$-13.12M$-0.10$-14.09M
Q3 '252025-09-30—$-16.13M$-0.21$-14.48M
Q2 '252025-06-30—$-10.36M$-0.13$-17.71M
Q1 '252025-03-31—$-6.00M$-0.08$-16.06M
Q4 '242024-12-31—$-41.73M$0.76$-18.99M
Q3 '242024-09-30—$54.43M$-0.32$-11.77M
Q2 '242024-06-30—$-39.03M$-0.92$-7.77M
Q1 '242024-03-31—$-10.29M$-0.34$-8.74M
Q4 '232023-12-31—$-30.10M$-0.94$-9.13M
Q3 '232023-09-30—$-9.91M$-0.33$-12.25M
Q2 '232023-06-30—$-65.76M$-2.74$-8.22M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-13
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.30
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-171.0%
ROA
-52.2%
Div Yield
0.00%
FCF Yield
-35.77%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$192.59M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
7.85M
SI % of Float
9.66%
Days to Cover
8.83
Short Vol Ratio
73.4%
Free Float
81.24M
Float %
100.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22